1-20 of 24
Suzanne George
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies

Michael C. Heinrich, Xinhua Zhang, Robin L. Jones, Suzanne George, César Serrano, Yanhong Deng, Sebastian Bauer, Shirong Cai, Xin Wu, Yongjian Zhou, Kaixiong Tao, Zhichao Zheng, Jun Zhang, Yuehong Cui, Hui Cao, Meining Wang, Jin Hu, Jason Yang, Jian Li, Lin Shen
Journal: Clinical Cancer Research
Clin Cancer Res (2023)
https://doi.org/10.1158/1078-0432.CCR-23-1861
Published: 30 November 2023
View article titled, Clinical Benefit of Avapritinib in <em>KIT-</em>Mutant Gastrointestinal Stromal Tumors: A <em>Post Hoc</em> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies
Open the PDF for Clinical Benefit of Avapritinib in <em>KIT-</em>Mutant Gastrointestinal Stromal Tumors: A <em>Post Hoc</em> Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies in another window
Includes: Supplementary data
Journal Articles

SAR-096: Phase II clinical trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS)

Sujana Movva, Sahar Matloob, Elizabeth A. Handorf, Edwin Choy, Priscilla Merriam, Douglas B. Flieder, Kathy Q. Cai, Yan Zhou, Eric D. Tetzlaff, Cheyenne Pagan, Emma Barker, Rosanna Veggeberg, Delia Zumpano, Lori Rink, Margaret von Mehren, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2023)
https://doi.org/10.1158/1078-0432.CCR-23-2469
Published: 15 November 2023
View article titled, SAR-096: Phase II clinical trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS)
Open the PDF for SAR-096: Phase II clinical trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS) in another window
Includes: Supplementary data
Journal Articles

Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma

Adrian Marino-Enriquez, Jan Philipp Novotny, Doga C. Gulhan, Isabella Klooster, Antuan V. Tran, Macy Kasbo, Meijun Z. Lundberg, Wen-Bin Ou, Derrick L. Tao, Daniel F. Pilco-Janeta, Victor Y. Mao, Frank T. Zenke, Brittaney A. Leeper, Prafulla C. Gokhale, Glenn S. Cowley, Laurence H. Baker, Karla V. Ballman, David E. Root, Joachim Albers, Peter J. Park, Suzanne George, Jonathan A. Fletcher
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF12.
https://doi.org/10.1158/1078-0432.CCR-23-0998
Published: 31 October 2023
View article titled, Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma
Open the PDF for Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma in another window
Includes: Supplementary data
Journal Articles

A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor

Suzanne George, Michael C. Heinrich, Neeta Somaiah, Peter Oppelt, Robert McLeod, Satoshi Nishioka, Madan G. Kundu, Xiaozhong Qian, Prasanna Kumar, Abderrahmane Laadem, Yvonne Lau, Brittany P. Tran, Maura Fallon, Ololade Dosunmu, Julia Shi, Yoichi Naito
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18): 3659–3667.
https://doi.org/10.1158/1078-0432.CCR-23-0640
Published: 15 September 2023
View article titled, A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
Open the PDF for A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor in another window
Includes: Supplementary data
Journal Articles

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James V. Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1412–1422.
https://doi.org/10.1158/1078-0432.CCR-22-3334
Published: 14 April 2023
View article titled, National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Open the PDF for National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) in another window
Includes: Supplementary data
Journal Articles

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

James Nguyen, Naoko Takebe, Shivaani Kummar, Albiruni Razak, Sant P. Chawla, Suzanne George, Shreyaskumar R. Patel, Mary Louise Keohan, Sujana Movva, Geraldine O'Sullivan Coyne, Khanh Do, Lamin Juwara, Brooke Augustine, Seth M. Steinberg, Laura Kuhlmann, S. Percy Ivy, James H. Doroshow, Alice P. Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1200–1208.
https://doi.org/10.1158/1078-0432.CCR-22-2145
Published: 03 April 2023
View article titled, Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
Open the PDF for Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma in another window
Journal Articles

Abstract A013: CDK2 and CDK4/6 inhibition in GIST: Mechanisms of response and resistance

Inga-Marie Schaefer, Matthew L. Hemming, Meijun Z. Lundberg, Matthew P. Serrata, Isabel Goldaracena, Ninning Liu, Peng Yin, Joao A. Paulo, Steven P. Gygi, Suzanne George, Jeffrey A. Morgan, Monica M. Bertagnolli, Ewa T. Sicinska, Adrian Mariño-Enríquez, Jason L. Hornick, Chandrajit P. Raut, George D. Demetri, Wen-Bin Ou, Sinem K. Saka, Jonathan A. Fletcher
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): A013.
https://doi.org/10.1158/1557-3265.SARCOMAS22-A013
Published: 15 September 2022
View article titled, Abstract A013: CDK2 and CDK4/6 inhibition in GIST: Mechanisms of response and resistance
Journal Articles

Linking Genotype to Phenotype: Bench to Bedside

Suzanne George, Monica M. Bertagnolli
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2725–2727.
https://doi.org/10.1158/1078-0432.CCR-22-0027
Published: 01 July 2022
View article titled, Linking Genotype to Phenotype: Bench to Bedside
Open the PDF for Linking Genotype to Phenotype: Bench to Bedside in another window
Journal Articles

Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma

Laura M. Madanat-Harjuoja, Kelly Klega, Yao Lu, David S. Shulman, Aaron R. Thorner, Anwesha Nag, William D. Tap, Denise K. Reinke, Lisa Diller, Karla V. Ballman, Suzanne George, Brian D. Crompton
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2579–2586.
https://doi.org/10.1158/1078-0432.CCR-21-3951
Published: 13 June 2022
View article titled, Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma
Open the PDF for Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma in another window
Includes: Supplementary data
Journal Articles

Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression

Matthew L. Hemming, Patrick Bhola, Michael A. Loycano, Justin A. Anderson, Madeleine L. Taddei, Leona A. Doyle, Elizaveta Lavrova, Jessica L. Andersen, Kelly S. Klega, Morgan R. Benson, Brian D. Crompton, Chandrajit P. Raut, Suzanne George, Anthony Letai, George D. Demetri, Ewa Sicinska
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2397–2408.
https://doi.org/10.1158/1078-0432.CCR-21-3523
Published: 01 June 2022
View article titled, Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression
Open the PDF for Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers

Suzanne George, Margaret von Mehren, Jonathan A. Fletcher, Jichao Sun, Sen Zhang, Justin R. Pritchard, John Graeme Hodgson, David Kerstein, Victor M. Rivera, Frank G. Haluska, Michael C. Heinrich
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1268–1276.
https://doi.org/10.1158/1078-0432.CCR-21-2037
Published: 01 April 2022
View article titled, Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers
Open the PDF for Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers in another window
Includes: Supplementary data
Journal Articles

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

Sebastian Bauer, Michael C. Heinrich, Suzanne George, John R. Zalcberg, César Serrano, Hans Gelderblom, Robin L. Jones, Steven Attia, Gina D'Amato, Ping Chi, Peter Reichardt, Julie Meade, Ying Su, Rodrigo Ruiz-Soto, Jean-Yves Blay, Margaret von Mehren, Patrick Schöffski
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6333–6342.
https://doi.org/10.1158/1078-0432.CCR-21-1864
Published: 01 December 2021
View article titled, Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <em>KIT/PDGFRA</em> Mutations in the Phase III INVICTUS Study
Open the PDF for Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <em>KIT/PDGFRA</em> Mutations in the Phase III INVICTUS Study in another window
Includes: Supplementary data
Journal Articles

Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement

Edward S. Kim, Thomas S. Uldrick, Caroline Schenkel, Suanna S. Bruinooge, R. Donald Harvey, Allison Magnuson, Alexander Spira, James L. Wade, Mark D. Stewart, Diana Merino Vega, Julia A. Beaver, Andrea M. Denicoff, Gwynn Ison, S. Percy Ivy, Suzanne George, Raymond P. Perez, Patricia A. Spears, William D. Tap, Richard L. Schilsky
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (9): 2394–2399.
https://doi.org/10.1158/1078-0432.CCR-20-3852
Published: 01 May 2021
View article titled, Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement
Open the PDF for Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement in another window
Journal Articles

Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade

César Serrano, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5078–5085.
https://doi.org/10.1158/1078-0432.CCR-20-1706
Published: 01 October 2020
View article titled, Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade
Open the PDF for Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade in another window
Journal Articles

Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study

Margaret von Mehren, Suzanne George, Michael C. Heinrich, Scott M. Schuetze, Jeffrey T. Yap, Jain Q. Yu, Amanda Abbott, Samuel Litwin, John Crowley, Martin Belinsky, Katherine A. Janeway, Jason L. Hornick, Douglas B. Flieder, Rashmi Chugh, Lori Rink, Annick D. Van den Abbeele
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1837–1845.
https://doi.org/10.1158/1078-0432.CCR-19-1069
Published: 15 April 2020
View article titled, Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study
Open the PDF for Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study in another window
Journal Articles

Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors

César Serrano, Alessandro Leal, Yanan Kuang, Jeffrey A. Morgan, Constance M. Barysauskas, Jillian Phallen, Olivia Triplett, Adrián Mariño-Enríquez, Andrew J. Wagner, George D. Demetri, Victor E. Velculescu, Cloud P. Paweletz, Jonathan A. Fletcher, Suzanne George
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7287–7293.
https://doi.org/10.1158/1078-0432.CCR-19-2150
Published: 13 December 2019
View article titled, Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
Open the PDF for Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors in another window
Includes: Supplementary data
Journal Articles

Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma

Ali Amin-Mansour, Suzanne George, Stefano Sioletic, Scott L. Carter, Mara Rosenberg, Amaro Taylor-Weiner, Chip Stewart, Aaron Chevalier, Sara Seepo, Adam Tracy, Gad Getz, Jason L. Hornick, Marisa R. Nucci, Bradley Quade, George D. Demetri, Chandrajit P. Raut, Levi A. Garraway, Eliezer M. Van Allen, Andrew J. Wagner
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (16): 5135–5142.
https://doi.org/10.1158/1078-0432.CCR-19-0271
Published: 15 August 2019
View article titled, Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma
Open the PDF for Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma in another window
Includes: Supplementary data
Journal Articles

Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines

John M. Goldberg, David E. Fisher, George D. Demetri, Donna Neuberg, Stephen A. Allsop, Catia Fonseca, Yukoh Nakazaki, David Nemer, Chandrajit P. Raut, Suzanne George, Jeffrey A. Morgan, Andrew J. Wagner, Gordon J. Freeman, Jerome Ritz, Cecilia Lezcano, Martin Mihm, Christine Canning, F. Stephen Hodi, Glenn Dranoff
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (14): 3178–3186.
https://doi.org/10.1158/1078-0432.CCR-14-2932
Published: 14 July 2015
View article titled, Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines
Open the PDF for Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines in another window
Journal Articles

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

Andrew J. Wagner, Rashmi Chugh, Lee S. Rosen, Jeffrey A. Morgan, Suzanne George, Michael Gordon, Joi Dunbar, Emmanuel Normant, David Grayzel, George D. Demetri
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (21): 6020–6029.
https://doi.org/10.1158/1078-0432.CCR-13-0953
Published: 31 October 2013
View article titled, A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas
Open the PDF for A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

Timothy A. Yap, Hendrik-Tobias Arkenau, D. Ross Camidge, Suzanne George, Natalie J. Serkova, Stephen J. Gwyther, Jennifer L. Spratlin, Rohit Lal, James Spicer, Nandita M. Desouza, Martin O. Leach, Jon Chick, Srinivasu Poondru, Ramesh Boinpally, Richard Gedrich, Katie Brock, Andrew Stephens, S. Gail Eckhardt, Stan B. Kaye, George Demetri, Michelle Scurr
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (4): 909–919.
https://doi.org/10.1158/1078-0432.CCR-12-2258
Published: 14 February 2013
View article titled, First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies
Open the PDF for First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies in another window
Includes: Supplementary data